title: Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.
abstract: BACKGROUND
  Invasive fungal infections are serious and life-threatening complications of many of today's medical enhancements. While we have seen an insurgence of new antifungal therapies on the market since the early 1990s that have contributed significantly to saving lives, there are still important gaps including narrow spectrum of activity, dose-limiting toxicities, or unpredictable pharmacokinetics. Isavuconazonium sulfate hopes to fill several of these gaps.
  
  
  METHODS
  The in vitro and in vivo pharmacology, pharmacokinetic characteristics, and phase 3 clinical trials for isavuconazole are described with a specific focus on the treatment of invasive aspergillosis and mucormycosis. A literature search was conducted in PubMed as well as FDA and EMA websites, and abstracts from congress proceedings. Expert Commentary: Isavuconazole's pharmacokinetic profile, broad-spectrum antifungal activity, and clinical trial data make this new triazole a welcome addition to the armamentarium.
authors.affiliation: a Astellas Pharma Global Development, Inc ., Northbrook , IL , USA.|b Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology , Institute of Translational Medicine, University of Liverpool , Liverpool , UK.
authors.forename: Laura L
authors.initials: LL
authors.lastname: Kovanda
authors.affiliation: a Astellas Pharma Global Development, Inc ., Northbrook , IL , USA.
authors.forename: Rochelle
authors.initials: R
authors.lastname: Maher
authors.affiliation: b Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology , Institute of Translational Medicine, University of Liverpool , Liverpool , UK.
authors.forename: William W
authors.initials: WW
authors.lastname: Hope
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D000072742:Invasive Fungal Infections / Q000188:drug therapy / Q000382:microbiology; D009091:Mucormycosis / Q000188:drug therapy* / Q000382:microbiology; D009570:Nitriles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D009570:Nitriles; D011725:Pyridines; D014230:Triazoles; C508735:isavuconazole
keywords: Isavuconazole; antifungal agent; aspergillosis; isavuconazonium sulfate; mucormycosis; triazole